Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019
About Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia is a malignant condition characterized by increased production of lymphocytes. It has been observed that the cancer first affects B-lymphocytes and then it can spread to other parts of the body. This leukemia is diagnosed mostly at later stages because of the slow buildup of the cancerous cells. During the course of the disease, the malignancy spreads to the spleen, liver, and lymph nodes. The course of the disease is heterogeneous, and prognosis is difficult. Symptoms include swelling of the lymph nodes, fatigue, fever, infection, pain beneath the ribs, and weight loss. Chronic lymphocytic leukemia can be treated with radiation, steroids, chemotherapy, targeted therapy, transplants (bone marrow, stem cell), and surgical procedure to remove the spleen (splenectomy).
Technavio's analysts forecast the global chronic lymphocytic leukemia therapeutics market to grow at a CAGR of 18.52% over the period 2014-2019.
Covered in this Report
In this report, Technavio covers the present scenario and growth prospects of the global chronic lymphocytic leukemia therapeutics market for the period 2015-2019. To calculate the market size, we consider revenue generated from the sales of various drugs used in the treatment of chronic lymphocytic leukemia.
Based on the type of molecule, we group the market into two categories:
Technavio Announces the Publication of its Research Report – Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019.
Technavio recognizes the following companies as the key players in the Global Chronic Lymphocytic Leukemia Therapeutics Market: F. Hoffmann-La Roche, Novartis and Teva Pharmaceutical Industries.
Other Prominent Vendors in the market are: Actavis, Amgen, Aryogen, Astellas, Bristol-Myers Squibb, Eagle Pharmaceuticals, Eisai, Fresenius Kabi, Genmab, Gilead Sciences, H. Lundbeck, Hospira, idd biotech, Immunomedics, Johnson & Johnson, Mundipharma, Mylan, Noxxon and Ono Pharmaceutical.
Commenting on the report, an analyst from Technavio’s team said: “Vendors are increasingly forming strategic alliances to increase their market shares. Co-development agreements allow the sharing of regulatory and developmental experiences gained by either company to support pipeline candidates.”
According to the report, “The increase in the patient pool for chronic lymphocytic leukemia is a major driver of the market. The elderly are more likely to be diagnosed with chronic lymphocytic leukemia. The older adult population is increasing globally, which indicates that the probability of getting chronic lymphocytic leukemia is also rising. As a result, the consumption of medications will increase, which will generate substantial revenue in the market.”
Further, the report states that the unknown etiology of chronic lymphocytic leukemia is a major challenge because vendors are unable to target the basic cause of the disease. This makes it difficult for them to develop a drug that can effectively treat and cure the disease.
F. Hoffmann-La Roche, Novartis and Teva Pharmaceutical Industries, Actavis, Amgen, Aryogen, Astellas, Bristol-Myers Squibb, Eagle Pharmaceuticals, Eisai, Fresenius Kabi, Genmab, Gilead Sciences, H. Lundbeck, Hospira, idd biotech, Immunomedics, Johnson & Johnson, Mundipharma, Mylan, Noxxon, Ono Pharmaceutical
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook